Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||-28%|
|Revenue Growth (QoQ)|
|Held by Institutions %||11%|
|1 Day Vol Adjusted Return||0.1|
|1 Month Vol Adjusted Return||0.1|
|3 Month Vol Adjusted Return||-4.3|
|6 Month Vol Adjusted Return||-3.8|
|20 Days SMA Price ZScore||0.3|
|50 Days SMA Price ZScore||-0.1|
|12 -26 Days PPO||-0.7|
|1 Month Average Short Volume Ratio||62.8|
|1 Day Volume Change ZScore||-0.7|
|1 Month Daily Vol||1.6|
HYDERABAD, India & PRINCETON, N.J., September 07, 2022--Dr. Reddy’s Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE: RDY). The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents. Related: Intercept Shares Jump After Reissuing Annual Guidance. Under the terms of the
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
HYDERABAD, India & PRINCETON, N.J., July 29, 2022--Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC.
HYDERABAD, India & PRINCETON, NJ, July 27, 2022--Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market.